Merck (NYSE: MRK) closed on its acquisition of Inspire Pharmaceuticals on Monday and disclosed more closure news – it will shut the Raleigh-based firm’s headquarters.

Inspire, which had been in financial trouble after a key respiratory drug candidate failed earlier this year, had recently moved to Raleigh from Durham and cut much of its staff. (Read details here.)

Merck bought Inspire for $5 a share, or some $430 million.

Inspire shares stopped trading on the Nasdaq as of Monday.

Merck plans to absorb Inspire’s ophthalmic business into Monarch Transaction Corp., a subsidiary of Merck.

Some Inspire executives will be leaving in coming weeks, and some Inspire workers could be moved to Merck’s drug production complex in Durham, a Merck spokesman said, according to media reports.

“We are excited to complete this compelling and highly complementary acquisition of Inspire,” said Beverly Lybrand, senior vice president and general manager, neuroscience and ophthalmology for Merck. “The successful completion of this transaction strengthens our ophthalmology business and positions us for future growth with an expanded portfolio and a best in class commercialization organization.”

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.